Skip to content
Company Analysis

Incyte Corporation INCY

A comprehensive view of key metrics, scores, and financial health for Incyte Corporation

Overview of Incyte Corporation

INCY NMS
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Large Cap
Incyte Corporation (INCY), is a Large Cap company, in the Biotechnology industry, last closed at $120.04, about 49.3% overvalued vs fair value, +14.1% 1Y return, placing in the top 10% of its sector.
Metrics P/E 15.4× Rev Growth 21.2% ROE 29.9% Gross Margin 92.8%
USD 120.04
-0.29%
(Delayed)
• Vol 90d: 31.4%
52-Week Range
Market Cap
$24.47B
Enterprise Value
$20.49B
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Excellent
Health
Good
Efficiency
Fair
Valuation
Fair
Growth
Good
Profitability
Excellent
Health
Good
Efficiency
Fair
Valuation
Fair
Completeness: 82%
Confidence: 91%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.incyte.com
HQ Wilmington, DE
Employees 2,844
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$56
$61
$66
Current: $120.04 -49% vs base

Engine Room Money Flow™

Large Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
$3.1B
83.5%%
Total Revenue
$5.1B
21.2%%
Net Income
$1.3B
3845%%
Operating Expense
$3.4B
-10.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

R&D Intensity
59.8%
Good

Solid R&D investment relative to operations

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
1
Active Leaks
1/1
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Incyte Corporation's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
82
/100
Strong
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.98), demonstrating pricing resilience across cycles.
  • ROIC Sustainably Above Peers ROIC at 89.1th percentile exceeds peers and WACC, demonstrating superior capital allocation.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Strong
83
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 67% Coverage
Trade-Off Triangle Visualization A ternary plot showing INCY's balance between Growth (39.1%), Profitability (21.0%), and Safety (39.9%). Growth 39% Safety 40% Profitability 21%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

62th percentile vs peers
62
Key Signals
TSR 9.6% 62p
Strengths
  • Cash to Debt Ratio in top 20% of peers (76.66, 90th percentile)
  • Growth above peer median with strong metric coverage (100%)
  • Conservative leverage compared to industry peers
Risks

No significant risks identified for this axis.

Profitability

- vs peers
-
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

63th percentile vs peers
63
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Incyte Corporation.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$60.90
- - -
-49.3% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000